NRX Pharmaceuticals, Inc. Increase (Decrease) in Accounts Payable
NRX Pharmaceuticals, Inc. (NRXP) reported Increase (Decrease) in Accounts Payable of -$1.12 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-14
- NRX Pharmaceuticals, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$1.25M.
- NRX Pharmaceuticals, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $129.00K, a 27.53% decline year-over-year.
- NRX Pharmaceuticals, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $13.00K.
- NRX Pharmaceuticals, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $601.00K, a 18.78% decline year-over-year.
- NRX Pharmaceuticals, Inc. increase (decrease) in accounts payable for fiscal 2025 was $113.00K.
- NRX Pharmaceuticals, Inc. increase (decrease) in accounts payable for fiscal 2024 was -$5.22M, a 296.50% decline from fiscal 2023.
- NRX Pharmaceuticals, Inc. increase (decrease) in accounts payable for fiscal 2023 was $2.65M.
- NRX Pharmaceuticals, Inc. increase (decrease) in accounts payable for fiscal 2022 was -$1.61M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 6 month as first filed | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 9 month as first filed | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$1.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$1.12M 10-Q · filed 2026-08-14 | -$1.11M derived: sum of 3 quarters · filed 2026-08-14 | -$510.00K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2026-03-31 | $129.00K 10-Q · filed 2026-05-15 | $142.00K derived: sum of 2 quarters · filed 2026-05-15 | $743.00K derived: sum of 3 quarters · filed 2026-05-15 | $64.00K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-12-31 | $13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $614.00K derived: sum of 2 quarters · filed 2026-03-23 | -$65.00K derived: sum of 3 quarters · filed 2026-08-14 | $113.00K 10-K · filed 2026-03-23 | ||
| 2025-09-30 | $601.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$78.00K derived: sum of 2 quarters · filed 2026-08-14 | $100.00K 10-Q · filed 2025-11-14 | -$10.07M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-06-30 | -$679.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$501.00K 10-Q · filed 2026-08-14 | -$10.67M derived: sum of 3 quarters · filed 2026-08-14 | -$9.93M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-03-31 | $178.00K 10-Q · filed 2026-05-15 | -$9.99M derived: sum of 2 quarters · filed 2026-05-15 | -$9.25M derived: sum of 3 quarters · filed 2026-05-15 | -$7.13M derived: sum of 4 quarters · filed 2026-05-15 | ||
| 2024-12-31 | -$10.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$9.43M derived: sum of 2 quarters · filed 2026-03-23 | -$7.31M derived: sum of 3 quarters · filed 2026-03-23 | -$5.22M 10-K · filed 2026-03-23 | ||
| 2024-09-30 | $740.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $2.86M derived: sum of 2 quarters · filed 2025-11-14 | $4.95M 10-Q · filed 2025-11-14 | $5.95M derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-06-30 | $2.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-18 | $4.21M 10-Q · filed 2025-08-18 | $5.21M derived: sum of 3 quarters · filed 2025-08-18 | $6.74M derived: sum of 4 quarters · filed 2025-08-18 | ||
| 2024-03-31 | $2.09M 10-Q · filed 2025-05-15 | $3.09M derived: sum of 2 quarters · filed 2025-05-15 | $4.62M derived: sum of 3 quarters · filed 2025-05-15 | $3.05M derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2023-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | $2.53M derived: sum of 2 quarters · filed 2025-03-14 | $957.00K derived: sum of 3 quarters · filed 2025-03-14 | $2.65M 10-K · filed 2025-03-14 | ||
| 2023-09-30 | $1.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$44.00K derived: sum of 2 quarters · filed 2024-11-14 | $1.65M 10-Q · filed 2024-11-14 | $1.56M derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2023-06-30 | -$1.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $129.00K 10-Q · filed 2024-08-14 | $37.00K derived: sum of 3 quarters · filed 2024-08-14 | -$873.00K derived: sum of 4 quarters · filed 2024-08-14 | ||
| 2023-03-31 | $1.70M 10-Q · filed 2024-05-14 | $1.61M derived: sum of 2 quarters · filed 2024-05-14 | $696.00K derived: sum of 3 quarters · filed 2024-05-14 | -$537.00K derived: sum of 4 quarters · filed 2024-05-14 | ||
| 2022-12-31 | -$92.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$1.00M derived: sum of 2 quarters · filed 2024-03-29 | -$2.23M derived: sum of 3 quarters · filed 2024-03-29 | -$1.61M 10-K · filed 2024-03-29 | ||
| 2022-09-30 | -$910.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$2.14M derived: sum of 2 quarters · filed 2023-11-14 | -$1.52M 10-Q · filed 2023-11-14 | -$3.39M derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | -$1.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$609.00K 10-Q · filed 2023-08-14 | -$2.48M derived: sum of 3 quarters · filed 2023-08-14 | -$3.19M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $624.00K 10-Q · filed 2023-05-15 | -$1.25M derived: sum of 2 quarters · filed 2023-05-15 | -$1.96M derived: sum of 3 quarters · filed 2023-05-15 | -$624.00K derived: sum of 4 quarters · filed 2023-05-15 | ||
| 2021-12-31 | -$1.87M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$2.58M derived: sum of 2 quarters · filed 2023-03-31 | -$1.25M derived: sum of 3 quarters · filed 2023-03-31 | -$19.00K 10-K · filed 2023-03-31 | ||
| 2021-09-30 | -$709.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $625.00K derived: sum of 2 quarters · filed 2022-11-14 | $1.85M 10-Q · filed 2022-11-14 | $1.85M 10-Q · filed 2021-11-15 | $1.71M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $1.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $2.56M 10-Q · filed 2022-08-15 | $2.56M 10-Q · filed 2021-08-16 | $2.42M derived: sum of 3 quarters · filed 2022-08-15 | $3.18M derived: sum of 4 quarters · filed 2022-08-15 | |
| 2021-03-31 | $1.23M 10-Q · filed 2022-05-16 | $1.08M derived: sum of 2 quarters · filed 2022-05-16 | $1.85M derived: sum of 3 quarters · filed 2022-08-12 | |||
| 2020-12-31 | -$147.18K derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-03-31 | $620.59K derived: sum of 2 quarters · filed 2022-08-12 | $1.18M 10-K · filed 2022-03-31 | |||
| 2020-09-30 | $767.77K derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2022-08-12 | $1.33M 10-Q/A · filed 2022-08-12 | ||||
| 2020-06-30 | $562.41K 10-Q/A · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |